Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review

被引：16

作者：

Matsumura, Koichiro ^{[1
]}

Sugiura, Tetsuro ^{[1
]}

机构：

[1] Kansai Med Univ, Med Ctr, Dept Cardiol, 10-15 Fumizono Cho, Moriguchi, Osaka 5708507, Japan

来源：

CARDIOVASCULAR ULTRASOUND | 2019年 / 17卷 / 01期

关键词：

Diabetes mellitus; Cardiac function; SGLT2; inhibitor; HEART-FAILURE; DIASTOLIC FUNCTION; OXIDATIVE STRESS; SGLT2; INHIBITION; EMPAGLIFLOZIN; DAPAGLIFLOZIN; FIBROSIS; CARDIOMYOPATHY; DYSFUNCTION; MORTALITY;

D O I：

10.1186/s12947-019-0177-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A high incidence of left ventricular diastolic dysfunction and increased risk of cardiovascular events have been reported in patients with diabetes mellitus. Sodium glucose cotransporter 2 (SGLT2) inhibitors selectively inhibit kidney glucose and sodium reabsorption, and cardiovascular benefits of SGLT2 inhibitors beyond other antidiabetic drugs have been reported in type 2 diabetes mellitus (T2DM) clinical trials. However, underlying mechanisms contributing to the improvement of cardiovascular outcomes have not been clearly identified. In this review, likely mechanisms of SGLT2 inhibitors contributing to a favorable cardiovascular outcomes are discussed based on experimental and clinical studies on cardiac function.

引用

页数：6

共 44 条

[1] Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System [J].

Ansary, Tuba M. ;

Nakano, Daisuke ;

Nishiyama, Akira .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03)

[2] Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis [J].

Baker, William L. ;

Smyth, Lindsay R. ;

Riche, Daniel M. ;

Bourret, Emily M. ;

Chamberlin, Kevin W. ;

White, William B. .

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (04) :262-275

[3]

Byrne Nikole J, 2017, JACC Basic Transl Sci, V2, P347, DOI 10.1016/j.jacbts.2017.07.003

[4] Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study [J].

Cohen, Neale D. ;

Gutman, Sarah J. ;

Briganti, Esther M. ;

Taylor, Andrew J. .

INTERNAL MEDICINE JOURNAL, 2019, 49 (08) :1006-1010

[5] Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction [J].

Connelly, Kim A. ;

Zhang, Yanling ;

Visram, Aylin ;

Advani, Andrew ;

Batchu, Sri N. ;

Desjardins, Jean-Francois ;

Thai, Kerri ;

Gilbert, Richard E. .

JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (01) :27-37

[6]

Fitchett David H, 2018, Eur Endocrinol, V14, P40, DOI 10.17925/EE.2018.14.2.40

[7] Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications [J].

Gerich, J. E. .

DIABETIC MEDICINE, 2010, 27 (02) :136-142

[8] Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients [J].

González-Vílchez, F ;

Ayuela, J ;

Ares, M ;

Pi, J ;

Castillo, L ;

Martín-Durán, R .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 101 (01) :53-58

[9] Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes [J].

Habibi, Javad ;

Aroor, Annayya R. ;

Sowers, James R. ;

Jia, Guanghong ;

Hayden, Melvin R. ;

Garro, Mona ;

Barron, Brady ;

Mayoux, Eric ;

Rector, R. Scott ;

Whaley-Connell, Adam ;

DeMarco, Vincent G. .

CARDIOVASCULAR DIABETOLOGY, 2017, 16

[10] Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes [J].

Hammoudi, Nadjib ;

Jeong, Dongtak ;

Singh, Rajvir ;

Farhat, Ahmed ;

Komajda, Michel ;

Mayoux, Eric ;

Hajjar, Roger ;

Lebeche, Djamel .

CARDIOVASCULAR DRUGS AND THERAPY, 2017, 31 (03) :233-246

← 1 2 3 4 5 →